By: IPP Bureau
Last updated : April 17, 2026 4:40 pm
The company reported net revenue of SEK 13.5 million for the full year 2025
Moberg Pharma has released its annual report for 2025, highlighting steady revenue growth alongside continued investments in product development and market expansion.
The company reported net revenue of SEK 13.5 million for the full year 2025, up from SEK 9.8 million in the previous year, reflecting gradual commercial progress.
Despite the revenue increase, Moberg Pharma posted an EBITDA loss of SEK 25.7 million and an operating loss (EBIT) of SEK 27.3 million, indicating ongoing spending on strategic initiatives and pipeline advancement.
The net result for the year was a loss of SEK 27.2 million, with diluted earnings per share at SEK -0.58.
The company maintained a solid financial position, with cash and cash equivalents totaling SEK 230.9 million at year-end, providing a strong runway to support continued commercialization and clinical activities.
Moberg Pharma’s 2025 performance reflects a transition phase, balancing early revenue traction with sustained investments aimed at strengthening its long-term growth prospects, particularly in dermatology-focused treatments and key international markets.